zaltenibart
Monoclonal antibody
Evidence outlook · no controlled comparison
NCT05972967 · Paroxysmal Nocturnal Hemoglobinuria
The lead study produced no formal comparison against a control: it had a single arm, or its primary endpoint did not compare the groups (for example, a safety count). This tier describes the design, not an outcome.
NCT05972967: This was a single-arm, open-label study with no comparison group in about 12 patients, and its primary measure was safety and tolerability, so it makes no controlled test of whether zaltenibart works. The interim report describes the drug as well tolerated, with treatment-related side effects in 46.2% of patients, mostly mild to moderate.
Interim results from a conference abstract (ASH 2024, data cut-off 8 July 2024); the registry posts no results and final data are not public.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT05889299 NCT05889299 · Paroxysmal Nocturnal Hemoglobinuria Registry: NCT05889299 | 1 | To Assess the Overall Safety and Tolerability of Zaltenibart (OMS906) Administration in PNH patients (48 weeks) 2025-11-03 | Results not posted; external-source review pending | not yet graded | link ↗ |
View 1 more trial
NCT05972967 NCT05972967 · Paroxysmal Nocturnal Hemoglobinuria This was a single-arm, open-label study with no comparison group in about 12 patients, and its primary measure was safety and tolerability, so it makes no controlled test of whether zaltenibart works. The interim report describes the drug as well tolerated, with treatment-related side effects in 46.2% of patients, mostly mild to moderate. Interim results from a conference abstract (ASH 2024, data cut-off 8 July 2024); the registry posts no results and final data are not public. Registry: NCT05972967 | 2 | To assess the overall OMS906 administration at 8-week intervals in PNH patients. (56 weeks) 2024-10-10 | Interim (data cut-off 8 July 2024): primary endpoints were safety and tolerability; zaltenibart was well tolerated, treatment-related adverse events in 46.2% of patients (mostly mild to moderate), 1 discontinuation for a treatment-emergent serious adverse event. Hemoglobin rose from a mean baseline of 9.26 g/dL by 3.39 g/dL at day 29 and 3.27 g/dL at day 169 on add-on to ravulizumab (N=13), and by 3.85 g/dL at day 309 on monotherapy (N=6, P=0.003). | Weak signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Paroxysmal Nocturnal Hemoglobinuria: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Zaltenibart: this drug | Phase 2 | Monoclonal antibody | MASP-3 | Weak signal | NCT05972967: Interim (data cut-off 8 July 2024): primary endpoints were safety and tolerability; zaltenibart was well tolerated, treatment-related adverse events in 46.2% of patients (mostly mild to moderate), 1 discontinuation for a treatment-emergent serious adverse event. Hemoglobin rose from a mean baseline of 9.26 g/dL by 3.39 g/dL at day 29 and 3.27 g/dL at day 169 on add-on to ravulizumab (N=13), and by 3.85 g/dL at day 309 on monotherapy (N=6, P=0.003). | |
| Eculizumab (Soliris) | Approved | Monoclonal antibody | Complement C5 | Weak signal | Featured results are safety only in this race | |
| Iptacopan (Fabhalta) | Approved | Small molecule | Complement Factor B | Partial signal | NCT04558918: At 24 weeks, without transfusion: Hb increase of 2 g/dL or more in 51 of 60 on iptacopan vs 0 of 35 on anti-C5; Hb of 12 g/dL or more in 42 of 60 vs 0 of 35. Superiority shown on both primaries. NCT04820530: Single arm, 24 weeks: estimated 92.2% (95% CI 82.5 to 100.0) of 40 complement-inhibitor-naive patients had a sustained Hb increase of 2 g/dL or more without transfusion. No comparator. | |
| Pegcetacoplan (Empaveli) | Approved | Peptide | Complement C3 | Partial signal | NCT03500549: Least Squares (LS) Mean Change From Baseline to Week 16 in Hemoglobin (Hb) Level During the RCP (Baseline and Week 16): Pegcetacoplan to Pegcetacoplan 2.37 Grams per deciliter (g/dL) (Standard Error 0.363) | Eculizumab to Pegcetacoplan -1.47 Grams per deciliter (g/dL) (Standard Error 0.666) | |
| Ravulizumab (Ultomiris) | Approved | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-5965 | Phase 3 | Undisclosed | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication | |
| Pozelimab (Veopoz) | Phase 3 | Monoclonal antibody | Complement C5 | not yet graded | No reviewed efficacy summary in this indication | |
| ALN-CFB | Phase 1/2 | RNA / oligonucleotide | Complement Factor B | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.